{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:19:06Z","timestamp":1791256746809,"version":"4.1.0"},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,1,5]]},"DOI":"10.18632\/oncotarget.6417","type":"journal-article","created":{"date-parts":[[2015,11,27]],"date-time":"2015-11-27T19:39:17Z","timestamp":1448653157000},"page":"845-859","source":"Crossref","is-referenced-by-count":23,"title":["Synergistic cooperation between ABT-263 and MEK1\/2 inhibitor: effect on apoptosis and proliferation of acute myeloid leukemia cells"],"prefix":"10.18632","volume":"7","author":[{"given":"Kelly","family":"Airiau","sequence":"first","affiliation":[{"name":"Laboratoire d'H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cibles Th\u00e9rapeutiques, INSERM 1035, Universit\u00e9 Bordeaux, Bordeaux, France"},{"name":"CHU Bordeaux, H\u00f4pital Haut-L\u00e9v\u00eaque, Laboratoire d'H\u00e9matologie, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Prouzet-Maul\u00e9on","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cibles Th\u00e9rapeutiques, INSERM 1035, Universit\u00e9 Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Rousseau","sequence":"additional","affiliation":[{"name":"Animalerie A2, Universit\u00e9 Bordeaux Segalen, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Pigneux","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cibles Th\u00e9rapeutiques, INSERM 1035, Universit\u00e9 Bordeaux, Bordeaux, France"},{"name":"CHU Bordeaux, H\u00f4pital Haut-L\u00e9v\u00eaque, Laboratoire d'H\u00e9matologie, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Jeanneteau","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, H\u00f4pital Haut-L\u00e9v\u00eaque, Laboratoire d'H\u00e9matologie, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manon","family":"Giraudon","sequence":"additional","affiliation":[{"name":"CHU Bordeaux, H\u00f4pital Haut-L\u00e9v\u00eaque, Laboratoire d'H\u00e9matologie, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoutar","family":"Allou","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cibles Th\u00e9rapeutiques, INSERM 1035, Universit\u00e9 Bordeaux, Bordeaux, France"},{"name":"CHU Bordeaux, H\u00f4pital Haut-L\u00e9v\u00eaque, Laboratoire d'H\u00e9matologie, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Dubus","sequence":"additional","affiliation":[{"name":"EA 2406 Histologie et Pathologie, Universit\u00e9 Bordeaux, Bordeaux, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Belloc","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cibles Th\u00e9rapeutiques, INSERM 1035, Universit\u00e9 Bordeaux, Bordeaux, France"},{"name":"CHU Bordeaux, H\u00f4pital Haut-L\u00e9v\u00eaque, Laboratoire d'H\u00e9matologie, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Xavier","family":"Mahon","sequence":"additional","affiliation":[{"name":"Laboratoire d'H\u00e9matopo\u00ef\u00e8se Leuc\u00e9mique et Cibles Th\u00e9rapeutiques, INSERM 1035, Universit\u00e9 Bordeaux, Bordeaux, France"},{"name":"CHU Bordeaux, H\u00f4pital Haut-L\u00e9v\u00eaque, Laboratoire d'H\u00e9matologie, Pessac, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2015,11,27]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.exphem.2009.04.002","article-title":"Acute myelogenous leukemia","volume":"37","author":"Butera","year":"2009","journal-title":"Exp Hematol"},{"key":"2","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Stockelberg","year":"2009","journal-title":"Blood"},{"key":"3","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2010-04-279794","article-title":"Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS\/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as \u201cAML not otherwise specified\u201d (AML-NOS) or \u201cAML with myelodysplasia-related changes\u201d (AML-MRC)","volume":"116","author":"Kohlmann","year":"2010","journal-title":"Blood"},{"key":"4","doi-asserted-by":"crossref","first-page":"3323","DOI":"10.1182\/blood.V89.9.3323","article-title":"Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study","volume":"89","author":"Chen","year":"1997","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1200\/JCO.2006.10.2731","article-title":"Acute myeloid leukemia and myelodysplastic syndromes in older patients","volume":"25","author":"Estey","year":"2007","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Godwin","year":"2006","journal-title":"Blood"},{"key":"7","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1038\/nrc883","article-title":"The Bcl2 family: regulators of the cellular life-or-death switch","volume":"2","author":"Adams","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.ceb.2006.10.004","article-title":"How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?","volume":"18","author":"Youle","year":"2006","journal-title":"Curr Opin Cell Biol"},{"key":"9","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood.V96.12.3932","article-title":"The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS","volume":"96","author":"Pagliuca","year":"2000","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","author":"Vasselon","year":"1993","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1600-0609.1999.tb01112.x","article-title":"Haematopoietic response and bcl-2 expression in patients with acute myeloid leukaemia","volume":"62","author":"Queiroz","year":"1999","journal-title":"Eur J Haematol"},{"key":"12","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/sj.onc.1210220","article-title":"The Bcl-2 apoptotic switch in cancer development and therapy","volume":"26","author":"Cory","year":"2007","journal-title":"Oncogene"},{"key":"13","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/blood.V81.1.151.151","article-title":"Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line","volume":"81","author":"Reed","year":"1993","journal-title":"Blood"},{"key":"14","first-page":"e2","article-title":"ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(\u2212) population to imatinib","volume":"40","author":"Belloc","year":"2012","journal-title":"Exp Hematol"},{"key":"15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.2007.06899.x","article-title":"ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms","volume":"140","author":"Yokota","year":"2008","journal-title":"Br J Haematol"},{"key":"16","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","article-title":"Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function","volume":"22","author":"Pages","year":"2003","journal-title":"Oncogene"},{"key":"17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1172\/JCI12807","article-title":"Therapeutic targeting of the MEK\/MAPK signal transduction module in acute myeloid leukemia","volume":"108","author":"Harris","year":"2001","journal-title":"The Journal of clinical investigation"},{"key":"18","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/sj.leu.2403859","article-title":"Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia","volume":"19","author":"Kaldjian","year":"2005","journal-title":"Leukemia"},{"key":"19","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1158\/1078-0432.CCR-13-1311","article-title":"Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial","volume":"20","author":"Popplewell","year":"2014","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"20","doi-asserted-by":"crossref","first-page":"e13026","DOI":"10.1371\/journal.pone.0013026","article-title":"Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim","volume":"5","author":"Roth","year":"2010","journal-title":"PLoS One"},{"key":"21","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1182\/blood-2011-03-340109","article-title":"The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma","volume":"118","author":"Gartenhaus","year":"2011","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/leu.2011.287","article-title":"MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1\/BIM complex","volume":"26","author":"Korchin","year":"2012","journal-title":"Leukemia"},{"key":"23","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4161\/cbt.6.4.4226","article-title":"Proteasome inhibition specifically sensitizes leukemic cells to anthracyclin-induced apoptosis through the accumulation of Bim and Bax pro-apoptotic proteins","volume":"6","author":"Lacombe","year":"2007","journal-title":"Cancer biology & therapy"},{"key":"24","doi-asserted-by":"crossref","first-page":"11752","DOI":"10.1073\/pnas.91.24.11752","article-title":"Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40","volume":"91","author":"Mignotte","year":"1994","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"25","doi-asserted-by":"crossref","first-page":"6477","DOI":"10.4049\/jimmunol.174.10.6477","article-title":"Human lymphoid and myeloid cell development in NOD\/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells","volume":"174","author":"Chaleff","year":"2005","journal-title":"Journal of immunology"},{"key":"26","first-page":"207","article-title":"Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors","volume":"115","author":"Talalay","year":"1981","journal-title":"Eur J Biochem"},{"key":"27","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.cub.2006.04.044","article-title":"Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression","volume":"16","author":"Nishida","year":"2006","journal-title":"Curr Biol"},{"key":"28","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1074\/jbc.M006132200","article-title":"Blockade of the extracellular signal-regulated kinase pathway induces marked G1 cell cycle arrest and apoptosis in tumor cells in which the pathway is constitutively activated: up-regulation of p27(Kip1)","volume":"276","author":"Kohno","year":"2001","journal-title":"J Biol Chem"},{"key":"29","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1073\/pnas.77.7.4123","article-title":"Prevalent deficiency in tumor cells of cycloheximide-induced cycle arrest","volume":"77","author":"Pardee","year":"1980","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"30","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Pettigrew","year":"2000","journal-title":"Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, UK"},{"key":"31","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/1078-0432.CCR-11-3090","article-title":"Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer","volume":"18","author":"Camidge","year":"2012","journal-title":"Clinical cancer research : an official journal of the American Association for Cancer Research"},{"key":"32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.leukres.2013.01.012","article-title":"The MYB oncogene can suppress apoptosis in acute myeloid leukemia cells by transcriptional repression of DRAK2 expression","volume":"37","author":"Gonda","year":"2013","journal-title":"Leukemia research"},{"key":"33","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Minhajuddin","year":"2013","journal-title":"Cell stem cell"},{"key":"34","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1111\/j.1476-5381.2012.02048.x","article-title":"Navitoclax (ABT-263) and bendamustine +\/\u2212 rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo","volume":"167","author":"Jin","year":"2012","journal-title":"British journal of pharmacology"},{"key":"35","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor","volume":"68","author":"Jin","year":"2008","journal-title":"Cancer research"},{"key":"36","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1002\/ijc.28236","article-title":"Antitumor activity of pimasertib, a selective MEK 1\/2 inhibitor, in combination with PI3K\/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells","volume":"133","author":"Capasso","year":"2013","journal-title":"International journal of cancer Journal international du cancer"},{"key":"37","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1756-8722-6-27","article-title":"MEK and the inhibitors: from bench to bedside","volume":"6","author":"Liu","year":"2013","journal-title":"Journal of hematology & oncology"},{"key":"38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Borthakur","year":"2014","journal-title":"Cancer discovery"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6417","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T18:56:32Z","timestamp":1718218592000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.6417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,27]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1,5]]}},"alternative-id":["6417","26625317"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.6417","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,27]]}}}